Aditxt, Inc. Acquires Evofem Biosciences, Inc.
December 12, 2023
Aditxt, Inc. has entered into a definitive agreement to acquire Evofem Biosciences in a stock-and-debt assumption transaction that will make Evofem a wholly owned subsidiary of Aditxt pending closing (anticipated H1 2024). The deal transfers approximately $100 million of consideration via stock issuance and assumption of certain senior indebtedness, and positions Aditxt to establish a women's health mission and scale Evofem’s hormone-free contraceptive Phexxi and other women's health products globally.
- Buyers
- Aditxt, Inc.
- Targets
- Evofem Biosciences, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Aditxt Inc. Signs Share Exchange Agreement to Acquire AiPharma Global Holdings LLC
December 28, 2021
Biotechnology
Aditxt Inc. (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly owned subsidiary of AiPharma Group Ltd., in a two-step transaction that initially transfers a 9.5% interest followed by the remaining 90.5% subject to closing conditions and shareholder/Nasdaq approvals. The deal would give Aditxt commercial presence in infectious disease therapeutics and access to AiPharma's rights to Avigan (favipiravir) and related antiviral assets and distribution networks.
-
Evotec SE Makes Strategic Equity Investment in IMIDomics, Inc.
February 15, 2022
Biotechnology
Evotec SE has made a minority equity investment in IMIDomics, Inc., and will take a board seat as part of the transaction; financial terms were not disclosed. The investment is intended to advance IMIDomics' Precision Discovery Engine and strengthen collaboration between Evotec and IMIDomics on data-driven drug discovery for immune-mediated inflammatory diseases.
-
Associated British Foods Acquires Fytexia from ArchiMed
February 2, 2022
Food & Beverage
Associated British Foods (ABF) has acquired French health-ingredients developer Fytexia from transatlantic private equity firm ArchiMed (MED I fund). The deal, which will fold Fytexia into ABF’s ABF Ingredients division, follows strong revenue and profit growth under ArchiMed’s ownership and returns MED I roughly four times its investment.
-
BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
Biotechnology
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
-
BiomX Acquires Adaptive Phage Therapeutics
March 18, 2024
Biotechnology
BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.
-
Danforth Advisors Acquires Advyzom
September 10, 2024
Healthcare Services
Danforth Advisors has acquired Advyzom, a New Jersey–based regulatory affairs consultancy of approximately 30 specialists, expanding Danforth's clinical and regulatory capabilities to offer a comprehensive suite of services for life science companies. The acquisition integrates Advyzom's regulatory strategy, FDA liaison, medical writing, and submissions expertise into Danforth's platform to better support clients across development, approval, and market entry.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.